CRF: PARTICIPANT INFORMATION

Participant Name		
Participant is de-identified	0	Yes
First Name	0	No
Middle Name		
Last Name		
Maiden / Other Name		
Patient Initials		
Participant Informatio	n	
Date of Birth		//
State of Birth		
Sex	0	Male
	0	Female
Race and Ethnicity		
Participant race		Caucasian / White
(check all that apply)		American Indian / Alaska Native
		Asian
		Native Hawaiian or Pacific Islander
		Black or African American
		More than One Race
		Other (specify) Unknown or Not Reported
		Olikilowii oli Not Nepolied
Other race (specify)		
Participant is Hispanic or Latino	0	Yes
	0	No
Contact Information		
Address		
City		
State		
Zip		
Phone		
Email		

CRF: CONSENT INFORMATION

Participant Consent	
Note: Unconsented data must be de-identified	
Consent Type	Institution-Specific IRBSchulman IRBIRB Waiver
Reason for waiver	Patient is deceasedOther
Other reason (specify)	
Per consent, patient allows USIDNET to contact him/her.	○ Yes○ No
Per consent, patient allows USIDNET to contact his/her physician.	○ Yes○ No
Consent allows sharing of data with CIBMTR and related research data platforms.	○ Yes○ No
CIBMTR Recipient ID Number	
PIDTC Recipient ID Number	
Additional data platforms per consent (if applicable)	

CRF: FAMILY HISTORY

Family History of PI		
Are there other patients with a primary immunodeficiency in the family?	○ Yes○ No○ Unknown	
How many relatives also have a PI?		
Did a positive family history prompt testing of this patient?	○ Yes○ No○ Unknown	
Are the parents of the patient related to each other?	○ Yes○ No○ Unknown	

Information on Affected Family Members		
Relation	Diagnosis	Listed in Registry?
		YesNoUnknown
		○ Yes○ No○ Unknown

Family History of Other Diseases		
	Has family history of disease	Disease present in
Autoimmune Diseases	YesNoUnknown	 Mother Father Sister Brother Daughter Son Other Female Relative Other Male Relative Relative Not Specified
Inflammatory Diseases	YesNoUnknown	 Mother Father Sister Brother Daughter Son Other Female Relative Other Male Relative Relative Not Specified
Malignancies	YesNoUnknown	 Mother Father Sister Brother Daughter Son Other Female Relative Other Male Relative Relative Not Specified

Family History of Other Diseases			
Relation	Genetic Testing?	Test Results	Gene Tested
	YesNoUnknown	 No Pathologic Variants X-Recessive Carrier Autosomal Recessive Carrier Same variant as proband without current health issues Unknown 	
	YesNoUnknown	 No Pathologic Variants X-Recessive Carrier Autosomal Recessive Carrier Same variant as proband without current health issues Unknown 	
	YesNoUnknown	 No Pathologic Variants X-Recessive Carrier Autosomal Recessive Carrier Same variant as proband without current health issues Unknown 	
	YesNoUnknown	 No Pathologic Variants X-Recessive Carrier Autosomal Recessive Carrier Same variant as proband without current health issues Unknown 	
	YesNoUnknown	 No Pathologic Variants X-Recessive Carrier Autosomal Recessive Carrier Same variant as proband without current health issues Unknown 	

Welcome to the FILL Program!

To begin, please select the appropriate evaluation



Initial Evaluation	Birth up to 6 months of age
Mid-year Evaluation (Follow-up)	From Initial Evaluation up to 1 year of age (After receiving primary series of killed vaccines, if given)
Annual Evaluation (Follow-up)	1 year up to 18 months of age, and annually thereafter
	This is a FILL visit

Visit covers up to the following date*	/
Which evaluation are you completing?	Initial EvaluationMid-Year EvaluationAnnual Evaluation

CRF: INITIAL REGISTRATION

Parent or Legal Guardian Info	rmation
First Name of Parent/Guardian	
Last Name of Parent/Guardian	
Email of Parent/Guardian	
Phone of Parent/Guardian	
Conoral Dationt Informati	
General Patient Informati Gestational age at birth	
	Weeks
Birth Weight	Grams
Twin or multiple birth?	○ Yes
Dragottod2	○ No
Breastfed?	○ Yes○ No
Evaluation Details	
Initial evaluation prompted by:	☐ Abnormal newborn screen test
(select all that apply)	☐ Positive family history
	☐ Clinical events or finding
Infection Type	Bacteria
	○ Fungal
	○ Viral
Physical Findings	○ No Proven Organism□ Heart Disease
Friysical Findings	☐ Hypoglycemia
	☐ Syndromic Features
Other (specify)	
Syndromic Features List features in the space provided.	
List reatures in the space provided.	

CRF: CLINICAL HISTORY

NO CLINICAL CONDITIONS PRESENT AT THIS TIME $\ \ \Box$ Select if applicable

Clinical Condition	IS .	
Select all that apply		Hydrops, edema, third spacing Hygroma or A-V malformation Chylous effusion GI malformation, atresia, gastroschisis Lymphangiectasia
Heart Anomaly	0	Yes No Unknown
Specific anomaly (if known)		
Heart surgery in the past 30 days	0	Yes No Unknown
Thymectomy?	0	Yes No Unknown
Infection		Bacteria Fungal Viral No Proven Organism
Neurological Abnormality		Seizures Hypotonia Other
Other neurological disorder (specify)		
Rash		Erythroderma Desquamation Maculopapular Eczema Other
Other rash (specify)		
Syndromic Features not L	isto	d Above
Please list all syndromic features for this patient.		

Non-Syndromic Features not Listed Above		
Please list all non-syndromic features for this patient.		
-		
-		
·		
-		
_		

CRF: IMMUNIZATIONS, INFUSIONS, TRANSFUSIONS

Live Vaccinations Given

Note: enter first valid determination for any of the following studies that were performed on your patient. You may leave blank any tests which were not performed or for which the data is not available.

leave blank any tests which were no	t performed of for which the data is not available.	
	# of Shots	
Measles	○ 1○ 2○ Total not known	
Mumps	○ 1○ 2○ Total not known	
Rotavirus	123Total not known	
Rubella	○ 1○ 2○ Total not known	
Varicella	 1 2 3 4 Total not known	
	Vaccines Withheld	
Withhold live rotavirus vaccine?	YesNoUnknown	
Withhold other vaccine(s)	YesNoUnknown	
	Other Vaccines Withheld	
Please include withheld vaccines in	this space	

immunogiobulin infusions			
Has patient ever rec	eived Ig Replacement Therapy?	YesNoUnknown	
Is patient currently of	on Ig replacement therapy?	YesNoUnknown	
Initiation	Start Date	///	-
	Start Age		_ months
			_ years
Termination	End Date	///	-
	End Age		_ months
			_ years
Dose			mg/kg
		·	_ Total grams
Route		IVSCIMUnknownOther	
	Other route (specify)		
Frequency			days
Was a port placed sp	pecifically for IVIG?	YesNoUnknown	
Transfusion Treatments			
Transfusion Precaut (CMV negative, leuk	ions Advised o-reduced, irradiated)	YesNoUnknown	

CRF: MEDICATIONS AND SUPPLEMENTS

Historical Anti-Infective Treatment			
Palivizumab (synagis) used during RSV activity in community	○ Yes○ No○ Unknown		

Prophylactic Anti-Infectives				
Please include all antibiotics, anti-virals, and anti-fungals (topical and systemic)				
Drug Name	Course	Adverse Reaction	Reaction	
	☐ Continuous☐ Intermittent☐ Rotating	○ Yes○ No○ Unknown		
	☐ Continuous☐ Intermittent☐ Rotating	YesNoUnknown		
	☐ Continuous☐ Intermittent☐ Rotating	YesNoUnknown		
	☐ Continuous☐ Intermittent☐ Rotating	YesNoUnknown		
	☐ Continuous☐ Intermittent☐ Rotating	○ Yes○ No○ Unknown		
	☐ Continuous☐ Intermittent☐ Rotating	YesNoUnknown		
	☐ Continuous☐ Intermittent☐ Rotating	○ Yes○ No○ Unknown		
	☐ Continuous☐ Intermittent☐ Rotating	○ Yes○ No○ Unknown		

Historical Immunomodulator Treatment			
Patient has used immunomodulatory medication in the past year	YesNoUnknown		

	Non-Transplant Immunomodulator Medications				
Please include all immunomodulator medications prescribed during the time period of this visit					
Drug Name	Indication	Specify	Improvement	Adverse Reaction	Reaction
	Treat DiseaseProphylaxisUnknown		YesNoUnknown	○ Yes○ No○ Unknown	
	Treat DiseaseProphylaxisUnknown		○ Yes○ No○ Unknown	○ Yes○ No○ Unknown	
	Treat DiseaseProphylaxisUnknown		○ Yes○ No○ Unknown	O Yes O No O Unknown	
	Treat DiseaseProphylaxisUnknown		○ Yes○ No○ Unknown	O Yes O No O Unknown	
	Treat DiseaseProphylaxisUnknown		○ Yes○ No○ Unknown	○ Yes○ No○ Unknown	
	Treat DiseaseProphylaxisUnknown		YesNoUnknown	○ Yes○ No○ Unknown	
	Treat DiseaseProphylaxisUnknown		YesNoUnknown	○ Yes○ No○ Unknown	

For-Transplant Immunomodulator Medication

Please include all immunomodulator medications prescribed during the time period of this visit

Drug Name	Indication	Adverse Reaction	Reaction	
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		
	 Stem Cell: PRE-transplant Stem Cell: POST-transplant Organ: PRE-transplant Organ: POST-transplant Unknown 	YesNoUnknown		

CRF: TRANSPLANTATION AND GENE THERAPY

	Trai	nsplantation	
Patient has undergone	e transplant	YesNoUnknown	
Type of transplant		☐ Hematopoietic Stem Cells☐ Solid Organ☐ Unknown	
		Cell Transplant	
Date of Transplant	Date	//	
	Age	months	
		years	
	Solid Or	gan Transplant	
Date of Transplant	Date	//	
	Age	months	
		years	
Which Solid Organ?	Other (specify)	 Kidney Liver Lung Heart Cornea Thymus Intestines Other 	
	Other (specify)		

Transplant Not Performed			
Transplant considered and not performed?	○ Yes○ No		
Solid Organ Other (specify)	 □ Lack of donor □ Age or condition of the patient □ Unfavorable probability of success □ Religious objections □ Insurance denial □ Hyper-immune status □ Other 		
Hematopoietic Stem Cell Transplant	 □ Lack of donor □ Age or condition of the patient □ Unfavorable probability of success □ Religious objections □ Insurance denial □ Other 		
Other (specify)			
Ger	e Therapy		
Patient has undergone gene therapy	YesNoUnknown		
Date of GT Date	//		
Age	months		
	years		

CRF: SURVIVAL & QUALITY OF LIFE

Patient Status			
Alive?	YesNoUnknown		
Date of Death	//		
Cause(s) of death	 □ Primary immunodeficiency □ Malignancy □ Infection □ Other Cause □ Unknown 		
Other (Specify)			

CRF: CORE LABORATORY TEST RESULTS

		TREC SCR	ENING	
Dried blood spo	t TREC screen) Done	
) Not Done	
Date of	Test		/	
Testing	Site		State NBS Lab	
J			Other Program	
			Other Lab	
	Other lah	(enocify)		
		(specify)		
If TREC	NON-NORMAL	, Result	Consistent with SCID	
			Unspecified	
) Inconclusive	
			Incomplete (Poor PCR)	
	Value	Туре	Units Result Term	
Control DNA		O B-actin	O copies/uL O Normal-adequ	ate
		○ RNAseP	○ Ct ○ Non-normal	
		Other:	O Not done / not	applicable
				I I'
TRECs			○ copies/uL ○ Normal	

○ Ct

O Non-normal

OTHER STUDIES		
Immune studies completed	□ PHA testing□ HIV Testing□ Maternal Lymph	ocyte Engraftment
OTHER STUDIES		
PHA studies performed	☐ PHA by Flow☐ PHA by 3H-thym	nidine
PHA by Flow		
Date of Test	//	
CD45 cells proliferating		6
Normal for CD45 Lab	>	%
CD3 cells proliferating		6
Normal for CD3 Lab	>	%
PHA by 3H-thymidi		
Date of Test	//	
Patient CPM Medium		
Patient CPM PHA		
Lab control CPM range medium		
Lab control CPM range with PHA**		
OTHER STUDIES		
	_	
Infant HIV by PCR or Pro		
Infant HIV Results	○ Positive (+)○ Negative (-)	
HIV Maternal Antibo		
HIV Maternal Antibody Results	Positive (+) Negative (-)	
Maternal Lymphocyte Eng		
Results	Searched for andSearched for and	
% of CD3	%	

Complete Blood Count					
Date of Test	//				
WBC	THOU/uL				
Platelets	THOU/uL				
RBC	MILL/uL				
Hgb	g/dL				
Lymphocytes	%	/uL			
PMN	%	/uL			
Eosinophils	%	/uL			
Monocytes	%	/uL			
	Lymphocyte Phenotype				
Date of Test	//				
Absolute Lymphocyte Count	/uL				
CD3 T Cells	%	/uL			
CD4 Helper T	%	/uL			
CD8 Cytotoxic T	%	/uL			
CD19 B Cells	%	/uL			
CD56/CD16 NK cells	%	/uL			
CD4 Subset Panel					
CD4 Subset Panel					
Date of Test	//				
	○ CD4+ CD45RA+○ CD4+ CCR7+ CD45RA+	%/uL			
	O CD4+ CD27+ CD45RA+				
	Other or unknown markers used				
	Immunoglobulin Evaluatio	on			
Date of Test /	/	ma/dl			
IgG	mg/dL IgG1 mg/dL IgG2	mg/dL mg/dL			
IgM	mg/dL lgG3	mg/dL			
IgE	IU/mL IgG4	mg/dL			
IgD	mg/dL	9,32			
	····g/ •-=				

OTHER STUDIES		
Vaccinations given		□ Diphtheria□ Pertussis□ Tetanus□ Pneumococcus
Pneumococcus vacc	cine type	☐ Conjugated vaccine☐ Unconjugated vaccine
Additional antibody tests		☐ Isohemagglutinin-Anti A☐ Isohemagglutinin-Anti B
	Vaccine Res	ponses
	# of shots	Response
Diphtheria	 ○ 1 ○ 2 ○ 3 ○ 4 ○ Total not known 	AbsentLowNormal
Tetanus	 ○ 1 ○ 2 ○ 3 ○ 4 ○ Total not known 	AbsentLowNormal
Pertussis	 ○ 1 ○ 2 ○ 3 ○ 4 ○ Total not known 	AbsentLowNormal
Isohemagglutinin – Anti A		AbsentLowNormal
Isohemagglutinin – Anti B		AbsentLowNormal
Unconjugated Pneumococcal Vaccine Response		
Date of Test		//
# of serotypes producing a protective level		serotypes
# of serotypes TESTED		serotypes

times

of times vaccine administered

Conjugated Pneumococcal Vaccine Response		
Date of Test	//	
# of serotypes producing a protective level # of serotypes TESTED		
Vaccine Name	 Prevnar 7 (PCV7) Prevnar 13 (PCV13) Other Unknown 	
# of times PCV7 administered		
# of times PCV13 administered		
# of times Other administered		
# of times Unknown administered		

CRF: MOLECULAR INFORMATION

Genetic Information	,	
Is this patient's PID linked to a gene mutation?	0	Yes; PI is linked to gene
	0	No; Gene not identified
	0	Gene tested; no mutation found
Gene Mutation		
Gene		
Mutation Type	0	Complex (hgvs/iscn)
,	Ŏ	Deletion
	\circ	Deletion/Insertion (indel)
	O	Duplication
	\bigcirc	Insertion
	0	Inversion Substitution
		Substitution
DNA Change		
Protein Change		
Zygosity	0	Homozygous
	Ŏ	Heterozygous
	\circ	X-Linked Hemizygous
	0	Unknown
Comments on how mutation was detected		
Gene		
Mutation Type	\circ	Complex (hgvs/iscn)
	0	Deletion
	\bigcirc	Deletion/Insertion (indel)
	0	Duplication
	Ö	Insertion Inversion
	Ŏ	Substitution
DNA Change		
Protein Change		
Zygosity		Номогиясия
Lygosity	0	Homozygous Heterozygous
	0	X-Linked Hemizygous
	\circ	Unknown
Comments on how mutation was detected		

Gene	
Mutation Type	 Complex (hgvs/iscn) Deletion Deletion/Insertion (indel) Duplication Insertion Inversion Substitution
DNA Change	
Protein Change	
Zygosity	HomozygousHeterozygousX-Linked HemizygousUnknown
Comments on how mutation was detected	

Testing Done; Mutation not Found		
Mutation Not Found: Gene		

Genetic / Genomic Testing				
Note: list positive result only; for pending results an	d negative results, fill in at later assessment times.			
Testing Performed	 ☐ Insertion/Deletion Analysis ☐ FISH for 22q deletion / DiGeorge Syndrome ☐ Whole exome / genome sequencing ☐ Karyotype ☐ Other ☐ NO TESTING DONE AT THIS TIME 			
Insertion / D	eletion Analysis			
Testing Performed	 □ Copy number array (CGH array) □ Multiplex ligation-dependent probe amplification (MPLA) □ SNP array □ Other 			
FISH	I Testing			
Result	Deletion DetectedNo Deletion Detected			
CG	H Array			
Copy Number Array: Result	Normal or non-contributory22q deletionOther abnormality			
Other: Specify	·			
Kai	ryotype			
Result	Normal or Non-ContributoryOther abnormality			
Othe	Other Testing			
Name of Test				
Result Other: Specify	Normal or Non-ContributoryOther abnormality			
Other: Specify				

CRF: DISEASE-SPECIFIC QUESTIONS

Diagnostic Criteria		
HIV has been excluded () Yes	
) No	
Select best diagnosis from list	31	
	Preterm birth alone	
	Syndrome with variable T cell impairment	
	Secondary T lymphopenia	
	Idiopathic T lymphopenia/not known at this time	
	No significant T lymphopenia or normal	
Typical / Leaky / Omenn		
Please Specify	Typical SCID	
	Leaky SCID	
	Omenn Syndrome	
Typical SCID	Absent or very low (< 300 /uL) T cells & absent or very low (< 10% of lower limit of normal) T cell function	
	T cells of maternal origin present, but with < 10% of lower limit of normal T cell function	
Leaky SCID (1)	<pre>< 1000/uL T cell # at < age 2 years</pre>	
С	< 800/uL T cell # at age 2 through < 4 years	
	<pre>< 600/uL T cell # at > 4 years</pre>	
	Maternal lymphocytes not detected	
Leaky SCID (2)	Absent proliferative responses to candida and tetanus toxoid antigens (post vaccination or exposure), with expression of HLA by flow/serology	
	Rule-out of MHC Class I and II non-expression by flow cytometry (or histology)	
	T cell function > 10% and < 30% of normal lower limit (as measured by response to PHA)	
Omenn Syndrome	Generalized skin rash	
С	Maternal lymphocytes not detected	
	Absent or low (< 30% lower limit of normal) T cell proliferation to antigens	
	> 80% of CD4 T cells are CD45R0+ (< 2 years of age)	

Syndrome with variable T-cell impairment Select best diagnosis from list Ataxia telangiectasia Cartilage Hair Hypoplasia O CHARGE syndrome (coloboma, heart defect, atresia choanae, retarded growth and development, genital and ear abnormality) O CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal anomalies) O DiGeorge / 22q deletion (or TBX1 mutation) □ DOCK8 Deficiency ☐ ECC syndrome (ectodermal dysplasia, ectrodactyly and clefting) ☐ EXTL3 deficiency ☐ Fryns syndrome (diaphragmatichernia and other congenital anomalies) ☐ Jacobsen Syndrome (growth and psychomotor retardation, congenital abnormalities, chromosome 11qter deletion) ☐ Nijmegen breakage syndrome □ Noonan syndrome (multiple congenital anomalies) ☐ RAC2 defect ☐ Renpenning syndrome ☐ Schimke disease ☐ TAR syndrome (thrombocytopenia, absent radius) ☐ Trisomy 18 ☐ Trisomy 21 ☐ Other DIAGNOSED multi-system syndrome ☐ Unknown or undefined syndrome: list symptoms

PEG-ADA Treatment		
Was this patient treated with PEG-ADA?	○ Yes	
	○ No	
	○ Unknown	
Is the patient currently on PEG-ADA?	○ Yes	
	○ No	
	○ Unknown	
Immune Reconstitution	O Full	
	Partial	
	O RX Failure	
Was ADA used as a "bridge" to another therapy?	○ Yes	
	○ No	
	○ Unknown	
Dose Schedule	units per week	